Lendvai et al. first described CD8+ T-cell reactions against MAGE-C1, which were detected in MM patients, and these CD8+ T-cell responses were restricted to patients expressing MAGE-C1 mRNA in their CD138+ myeloma cells. This evidence concerns the gene MAGEC1 and Miyoshi myopathy.